HOME >> BIOLOGY >> NEWS
New study confirms process leading to disorder causing male characteristics in women

(June 22, 2004) - Bethesda, MD -- A woman finds herself with excessive facial hair, obesity, menstrual abnormalities, infertility, and enlarged ovaries may have polycystic ovary syndrome (PCOS), an unfortunate condition thought to be caused by excessive secretion by the ovaries of androgen, a hormone associated with male characteristics. Men and women both have hormones expressing male and female characteristics. Yet, the cause of this excessive secretion of a hormone leading to undesired gender traits remains unclear.

Estimates of incidence of this disorder range around the five percent level if both cessation of ovulation and excess hair growth are used in the definition, but they can range over 10 percent in some select populations. Past research emphasized the relative roles of neuroendocrine abnormalities leading to persistent and excessive secretion of luteinizing hormones (LH), one of two glycoprotein hormones that stimulate the final ripening of the follicles and the secretion of progesterone; and the ovarian actions increased insulin in plasma, a consequence of insulin resistance. Additional evidence suggests that unnatural ovarian production of hormonal steroids is a primary abnormality in PCOS.

Human studies of PCOS have found abnormal ovarian steroid responses to administration of gonadial hormones, specifically potent gonadotropin-releasing hormone (GnRH) agonist or a high dose of human chorionic gonadotropin (hCG). The stimuli cause exaggerated secretion of 17-hydroxyprogesterone (17-OHP) and, to a lesser degree, androstenedione, suggesting abnormal ovarian production of steroids. However, these paradigms involve pharmacological ovarian stimulation and do not reproduce physiological LH pulsatility.

Researchers recently hypothesized that near-physiological LH stimuli would effect greater ovarian secretion of androgens and their precursors in women with PCOS compared to controls. To test this supposition, they employe
'"/>

Contact: Mayer Resnick
mresnick@the-aps.org
301-634-7209
American Physiological Society
22-Jun-2004


Page: 1 2 3

Related biology news :

1. Student science contest participation influences study, career choices, alumni say
2. New study shows hope for treating inhalant abuse
3. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
4. Cigarette smoke causes breaks in DNA and defects to a cells chromosomes, Pitt study finds
5. New study indicates arsenic could be suitable as first-line treatment in type of leukaemia
6. Phase II trials of second-generation antisense cancer drug planned following successful early study
7. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
8. Indiana University, EPA to study airborne PCBs
9. K-State, other universities to study how climate affects plant evolution
10. USC study links historical increases in life span to lower childhood exposure to infection
11. Washington University in St. Louis leads group studying aging process

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 Report ... ... and should reach $11.4 billion by 2021, growing at a ... Report Includes - An overview of the global markets for ... from 2015, estimates for 2016, and projections of compound annual ...
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... 2017   Capricor Therapeutics, Inc. (NASDAQ: ... developing first-in-class biological therapies for cardiac and other ... to terminate its license agreement with the Mayo ... Cenderitide. "Our decision to return these ... our efforts to advance our core cell and ...
(Date:2/16/2017)... , Feb. 16, 2017  Champions Oncology, Inc. ... the development and sale of advanced technology solutions and ... drugs, today announced the addition of new cohorts of ... These new models will expand Champions, product line in ... and neck cancer, AML, and non-small cell lung cancer ...
(Date:2/16/2017)... WEST LAFAYETTE, Indiana (PRWEB) , ... ... ... a division of Albany Molecular Research Inc. has further extended its industry ... sector. This service offers state-of-the-art cGMP techniques and methods for the ...
(Date:2/15/2017)... Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial ... full year ended December 31, 2016. ... we continued to demonstrate strong growth in our ... said Mihael H. Polymeropoulos, M.D., Vanda,s President and ... 2017 milestones underscores Vanda,s commitment to bringing important ...
Breaking Biology Technology:
Cached News: